Genflow Biosciences PLC Announces Result of GM

NYSE - LSE

RIO	-1.34%	98.04	$
BTI	-0.6%	62.28	$
BP	0.71%	39.135	$
GSK	-0.87%	58.61	$
CMSC	-0.43%	23.41	$
CMSD	-0.34%	23.31	$
AZN	-1.34%	205.64	$
NGG	-0.83%	93.01	$
BCC	-2.98%	80.366	$
JRI	0.63%	13.22	$
BCE	-0.88%	26.08	$
RYCEF	-0.76%	18.32	$
RELX	-0.71%	34.545	$
VOD	-1.79%	15.09	$
RBGPF	0.12%	82.5	$

Genflow Biosciences PLC Announces Result of GM

BOULEVARD 02.03.2026

Results of General Meeting

Text size:

LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Votes withheld	Total votes cast
1. To approve the Director's authority to allot securities.	224,571,419	98.2%	3,787,114	1.7%	429,987	228,788,520
Special Resolution	Votes for	% of votes cast for	Votes Against	% of votes cast against	Votes withheld	Total votes cast
2. To disapply statutory pre-emption rights.	222,245,570	97.1%	5,141,463	2.2%	1,401,487	228,788,520

Contacts Genflow Biosciences	Harbor Access
Dr Eric Leire, CEO	Jonathan Paterson, Investor Relations
+32-477-495-881	+1 475 477 9401
[email protected]

About Genflow

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, delivers a proprietary centenarian variant of the SIRT6 gene. The therapy is currently being evaluated in the Company's randomised, blinded SLAB (Sarcopenia and Longevity in Aged Beagles) study in dogs aged over 10 years, which commenced in March 2025. Preliminary interim results demonstrated improved survival versus control during the dosing period, alongside favourable safety and tolerability and positive trends across functional endpoints including muscle mass preservation, frailty reduction and quality of life. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Genflow Biosciences PLC

View the original press release on ACCESS Newswire

L.Durand--AMWN

American Marconi Wireless News - Genflow Biosciences PLC Announces Result of GM

Genflow Biosciences PLC Announces Result of GM

Featured

Bangladesh tackle gender barriers to reach Women's Asian Cup

Black Book Market Research Releases "China: State of Acute Care EHR and Digital Health 2026"

Medical Care Technologies Inc. (OTC PINK:MDCE) Snapshot Recipes Reaches #12 in Food & Drink on Apple iOS Ahead of Major Marketing Push

EDGE Surgical Launches 40mm and 120mm Electronic Depth Gauges